Avalo Therapeutics (AVTX) Interest Expenses (2014 - 2026)
Avalo Therapeutics (AVTX) posted Interest Expenses of $23.8 million for Q1 2026, up 264344.44% on a QoQ basis from $9000.0 in Q4 2025, and up 39566.67% year-over-year from N/an in Q1 2025.
Avalo Therapeutics (AVTX) Interest Expenses (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Interest Expenses history runs 13 years deep, the most recent figure standing at $23.8 million for Q1 2026.
- Quarterly Interest Expenses rose 39566.67% year-over-year to $23.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.8 million (up 10070.94% YoY) and the FY2025 annual result came in at $39.9 million, down 39.23% from the prior year.
- Interest Expenses was $23.8 million for Q1 2026 at Avalo Therapeutics, up from $9000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $23.8 million in Q1 2026 and bottomed at $9000.0 in Q4 2025.
- A 5-year average of $2.4 million and a median of $358000.0 in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses sank 97.98% — and 2026, when it jumped 39566.67%.
- Avalo Therapeutics' Interest Expenses stood at $675000.0 in 2022, then surged by 264.0% to $2.5 million in 2023, then tumbled by 97.56% to $60000.0 in 2024, then slumped by 85.0% to $9000.0 in 2025, then soared by 264344.44% to $23.8 million in 2026.
- Business Quant data shows AVTX's Interest Expenses at $23.8 million in Q1 2026, $9000.0 in Q4 2025, and $59000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 32.89 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 16.81 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.17 Bn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 23.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.80 Mn |
| Mar 31, 2026 | 23.80 Mn |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 59,000.00 |
| Sep 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 117,000.00 |
| Jun 30, 2025 | 117,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Sep 30, 2024 | 56,000.00 |
| Sep 30, 2024 | 56,000.00 |
| Jun 30, 2024 | 58,000.00 |
| Jun 30, 2024 | 58,000.00 |
| Mar 31, 2024 | 55,000.00 |
| Mar 31, 2024 | 55,000.00 |
| Sep 30, 2023 | 2.46 Mn |
| Sep 30, 2023 | 2.46 Mn |